Remicade infliximab: Phase II data; marketed to treat rheumatoid arthritis (RA) and Crohn’s disease

In a double-blind, placebo-controlled Phase II study of 33 psoriasis patients, 5 and 10 mg/kg of Remicade gave 82 and 91 percent response rates, respectively, compared to 18 percent for placebo patien...